DR. CHRISTOPHER JONES
Neurology at Chipeta Way, Salt Lake City, UT

2013010, Apr 25, 2013

Oct 4, 2012

13/644614

Dean Li - Salt Lake City UT, US
Christopher Jones - Salt Lake City UT, US
Nyall London - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

A61K 38/17

514 133, 435 29, 530328, 530327, 530326, 530325, 530324, 530350, 536 235, 4353201, 514 44 R

Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein.

2006013, Jun 22, 2006

Nov 26, 2003

10/536735

Louis Ptacek - San Francisco CA, US
Christopher Jones - Salt Lake City UT, US
Ying Fu - San Francisco CA, US

C12Q 1/68, C07H 21/04, C12P 21/06, C12N 9/12

435006000, 435069100, 435194000, 435320100, 435325000, 536023200

Genetic variants of the casein kinase I delta and casein kinase I epsilon genes are disclosed. Herein, two novel mutant casein kinase I delta genes and a novel mutant casein kinase I epsilon gene are disclosed. The protein products of the mutant casein kinase I delta gene and the mutant casein kinase I epsilon gene are also disclosed. The nucleic acid sequences of the invention lead to familial advanced sleep phase syndrome.